Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Plasmacytoid dendritic cells promote HIV-1–induced group 3 innate lymphoid cell depletion
Zheng Zhang, … , Fu-Sheng Wang, Lishan Su
Zheng Zhang, … , Fu-Sheng Wang, Lishan Su
Published August 24, 2015
Citation Information: J Clin Invest. 2015;125(9):3692-3703. https://doi.org/10.1172/JCI82124.
View: Text | PDF
Research Article AIDS/HIV Article has an altmetric score of 2

Plasmacytoid dendritic cells promote HIV-1–induced group 3 innate lymphoid cell depletion

  • Text
  • PDF
Abstract

Group 3 innate lymphoid cells (ILC3s) have demonstrated roles in promoting antibacterial immunity, maintaining epithelial barrier function, and supporting tissue repair. ILC3 alterations are associated with chronic inflammation and inflammatory disease; however, the characteristics and relevant regulatory mechanisms of this cell population in HIV-1 infection are poorly understood due in part to a lack of a robust model. Here, we determined that functional human ILC3s develop in lymphoid organs of humanized mice and that persistent HIV-1 infection in this model depletes ILC3s, as observed in chronic HIV-1–infected patients. In HIV-1–infected mice, effective antiretroviral therapy reversed the loss of ILC3s. HIV-1–dependent reduction of ILC3s required plasmacytoid dendritic cells (pDCs), IFN-I, and the CD95/FasL pathway, as targeted depletion or blockade of these prevented HIV-1–induced ILC3 depletion in vivo and in vitro, respectively. Finally, we determined that HIV-1 infection induces CD95 expression on ILC3s via a pDC- and IFN-I–dependent mechanism that sensitizes ILC3s to undergo CD95/FasL-mediated apoptosis. We conclude that chronic HIV-1 infection depletes ILC3s through pDC activation, induction of IFN-I, and CD95-mediated apoptosis.

Authors

Zheng Zhang, Liang Cheng, Juanjuan Zhao, Guangming Li, Liguo Zhang, Weiwei Chen, Weiming Nie, Natalia J. Reszka-Blanco, Fu-Sheng Wang, Lishan Su

×

Figure 1

HIV-1 disease progression is associated with depletion of ILC3 cells in human patients.

Options: View larger image (or click on image) Download as PowerPoint
HIV-1 disease progression is associated with depletion of ILC3 cells in ...
(A) Representative FACS plots show the proportion of ILC3s in peripheral blood of enrolled human subjects. The numbers indicate the percentages of ILC3s (CD127+CD117+ cells) within CD45+Lin– cells. VL, viral load. (B) Summary data of percentages of ILC3s in CD45+Lin– cells in HC subjects (n = 20), HIV-1–infected patients with CD4+ T cell counts of more than 400 cells/μl (n = 18), and those with CD4+ T cell counts of fewer than 400 cells/μl (n = 37). Overall, P = 0.003, 1-way ANOVA; P values shown in the figures are based on Tukey’s post-hoc test. (C) Correlation analysis between the percentages of ILC3s and plasma HIV-1 loads, LPS activity, and sCD14 levels (Spearman rank correlation test). r, correlation coefficient. (D) Costaining of CD3 with IL-17 or IL-22 in colon mucosal specimens from HIV-1–negative and HIV-1–positive subjects by confocal microscopy. Original magnification, ×400. Representative staining shows CD3+ (green), IL-17+, and IL-22+ (red) cells. DAPI was used to counterstain nuclear DNA (blue). The insert shows CD3+IL-17+ or CD3+IL-22+ Th17 cells and CD3–IL-17+ or CD3–IL-22+ ILC3s. (E) Immunohistochemical costaining for mucosal CD3+IL-17+ Th17 cells (black arrows) and CD3–IL-17+ ILC3 cells (yellow arrows) in colons of HIV-1–uninfected and HIV-1–infected subjects. hpf, ×400.(F) Numbers of colon mucosal CD3+ T cells, Th17 cells, and ILC3 cells are calculated in various subjects (2-tailed unpaired Student’s t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
On 1 Facebook pages
68 readers on Mendeley
See more details